The National Institutes of Health is wading into the drug development process by making grants to find and develop drugs for rare diseases, often called orphan diseases, according to the Wall Street Journal (subscription required).
Under a program announced Wednesday, the nation’s medical research agency also would target medicines for diseases, like malaria, that are rare in the United States but plague people who live in tropical regions of the world, the Journal said.
“We’ve never tried to directly develop medicines for rare and neglected diseases,” said NIH Acting Director Raynard Kington while announcing the new grant program. NIH traditionally has made mostly basic science grants, not grants to support development to get drugs ready for human testing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The $24 million program jump starts the Therapeutics for Rare and Neglected Diseases program, which will span NIH centers, the agency said. The program is unusual because it is aimed at creating the NIH’s first drug development pipeline and collaboration among researchers who work on rare illnesses.
The program comes with new money from Congress that’s aimed at finding new treatments for 6,800 rare illnesses that affect about 25 million Americans, the Journal said. Of these diseases, only 200 have treatments, NIH said.
Drug companies often shy away from finding or developing treatments for orphan or neglected diseases because it often is unprofitable work and doesn’t offer sufficient return on investment.
More stories worth a read:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
- Baucus: Health care reform will not cover all Americans (MedPage Today)
- Bid to repeal life sciences bill thwarted in Massachusetts senate (MassDevice)
- Readers say nursing unions are a big plus (FierceHealthcare, Anne Zieger column)
- Independence: Cleveland Clinic could bring in 600 jobs (Independence Sun Courier)
- Study: Hospitals that charge more fare worse on quality measures (Wall Street Journal Health blog)
- New data show failure of reform is not an option (BNET Healthcare)
- Grants shed light on needs of poor (Cincinnati Enquirer)
- Medtronic announces FDA approval of two deep brain stimulation devices that offer programming advances and new tools for patients with movement disorders (BusinessWire)
- Lakewood Hospital staff pledges gifts for planned renovation (Crain’s Cleveland Business)
- Maryland governor unfeils 17-point biotech plan (Washington Business Journal)
- Workers at Doctors hospital vote to join new union, dump SEIU (San Francisco Business Times)
- J&J buys Cougar Biotech for $1 billion(FierceBiotech)
- 2nd death in New York City linked to swine flu (New York Times)
- Ohio avoids worst of flu outbreak (Columbus Dispatch)
- U.S. to spend $1 billion on H1N1 flu vaccine production (Wall Street Journal; subscription required)
- OmnicareCEO sees steady demand for its services (Business Courier of Cincinnati)
